2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139909
    CL2E-SN38
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
    CL2E-SN38
  • HY-160247
    Boc-Lys-PEG8-N-bis(D-glucose)
    Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2.
    Boc-Lys-PEG8-N-bis(D-glucose)
  • HY-128910
    MC-VC(S)-PABQ-Tubulysin M
    MC-VC(S)-PABQ-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) (HY-N7053) and MC-VC(S)- PABQ (an ADC linker) is connected. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors.
    MC-VC(S)-PABQ-Tubulysin M
  • HY-160143
    G3-VC-PAB-DMEA-Duocarmycin DM
    G3-VC-PAB-DMEA-Duocarmycin DM (Compound LD-1) is a duocarmycin-based linker molecule that can be used for ADC preparation..
    G3-VC-PAB-DMEA-Duocarmycin DM
  • HY-163683
    EB-PSMA-617
    EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity.
    EB-PSMA-617
  • HY-153976
    Fmoc-Gly3-VC-PAB-MMAE
    Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker.
    Fmoc-Gly3-VC-PAB-MMAE
  • HY-158351
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate for ADC.
    Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag
  • HY-141593
    Modified MMAF-C5-COOH
    Modified MMAF-C5-COOH is a agent-linker conjugate for ADC.
    Modified MMAF-C5-COOH
  • HY-153067
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a coupling compound that can be used for the synthesis of ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan synthesized ADC shows good antitumor activity in vitro and in vivo.
    Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
  • HY-160893
    PSMA-Val-Cit-PAB-Azide
    		99.43%
    PSMA-Val-Cit-PAB-Azide is a drug-linker conjugate for ADC. PSMA-Val-Cit-PAB-Azide contains the cleavable ADCs linker (Val-Cit-PAB) and a novel small-molecule PSMA-targeted conjugate. It contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups.
    PSMA-Val-Cit-PAB-Azide
  • HY-16215
    Mipsagargin
    Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research.
    Mipsagargin
  • HY-156896
    Val-Cit-amide-Cbz-N(Me)-Maytansine
    Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs).
    Val-Cit-amide-Cbz-N(Me)-Maytansine
  • HY-160702
    DMBA-SIL-Mal-MMAE
    DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal.
    DMBA-SIL-Mal-MMAE
  • HY-148339
    Fmoc-VAP-MMAE
    Fmoc-VAP-MMAE is a agent-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE (HY-15162), with a protective Fmoc group.
    Fmoc-VAP-MMAE
  • HY-128941
    CCK2R Ligand-Linker Conjugates 1
    CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.
    CCK2R Ligand-Linker Conjugates 1
  • HY-126493
    DM4-SPDP
    DM4-SPDP is a agent-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody agent conjugate. SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls.
    DM4-SPDP
  • HY-131085
    Desmethyl Vc-seco-DUBA
    Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).
    Desmethyl Vc-seco-DUBA
  • HY-155744
    Acetylene-PEG3-MMAF-OMe
    Acetylene-PEG3-MMAF-OMe (LCB14-0536) is a protein-active agent conjugate. Acetylene-PEG3-MMAF-OMe can be recognized by isoprenoid transferase. Acetylene-PEG3-MMAF-OMe is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-PEG3-MMAF-OMe
  • HY-145365
    DGN549-L
    DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs).
    DGN549-L
  • HY-137774
    Clezutoclax
    Clezutoclax is a potent payload and also a Bcl-XL inhibitor. Clezutoclax can be used in the synthesis of antibody-drug conjugates (ADCs).
    Clezutoclax
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.